Clinical application of Epstein-Barr virus DNA loads in Epstein-Barr virus-associated diseases: A cohort study

Shenglei Yu,Qingluan Yang,Jing Wu,Mengqi Zhu,Jingwen Ai,Haocheng Zhang,Bin Xu,Lingyun Shao,Wenhong Zhang
DOI: https://doi.org/10.1016/j.jinf.2020.11.027
2021-01-01
Abstract:Objectives: This study evaluated the diagnostic value of Epstein-Barr virus (EBV) DNA load in blood samples of patients with EBV-associated diseases, and proposed a strategy for the interpretation of positive EBV DNA results. Methods: Derivation and validation cohorts were established to evaluate the clinical significance of EBV DNA loads in the peripheral blood mononuclear cells (PBMCs) and plasma from EBV-infected patients. EBV DNA loads were compared and receiver operating characteristic curves were employed to assess the optimal cutoff values of EBV DNA for identification of EBV-associated diseases. Results: The derivation and validation cohorts comprised 135 and 71 subjects, respectively. EBV DNA loads in the PBMCs of the EBV-associated diseases group was significantly higher than that of the EBV non-associated diseases group (5.8 x 10(4) vs 7.8 x 10(3) copies/10(6) cells, P<0.0001). The diagnostic cut-offvalue of viral load in PBMCs for EBV-associated diseases was determined to be 1.6 x 10(4) copies/10(6) cells. The combined EBV DNA load cutoff in PBMCs and positive EBV DNA qualitative detection in plasma (>500 copies/mL) allowed for the differentiation of EBV-associated and non-associated diseases; the sensitivity and specificity were 80.6 and 96.8%, respectively. Conclusions: The strategy of combining EBV DNA loads in PBMCs and plasma will potentially help identify EBV-associated diseases. (C) 2020 Published by Elsevier Ltd on behalf of The British Infection Association.
What problem does this paper attempt to address?